Literature DB >> 1516405

Multidrug resistant Mycobacterium tuberculosis in patients with human immunodeficiency virus infection.

C P Busillo1, K D Lessnau, V Sanjana, S Soumakis, M Davidson, M P Mullen, W Talavera.   

Abstract

Multidrug resistant Mycobacterium tuberculosis (MDR-MTB) infection has not been recognized as a serious problem in patients with human immunodeficiency virus (HIV) infection. Multidrug resistance (MDR) has appeared in our medical center in 24 out of 72 patients between January 1990 and May 1991 compared to 8 out of 132 patients within the period from 1982 to 1987 (relative risk 5.50 with 95 percent confidence interval 2.61 to 11.61). We describe 19 patients with MDR in MTB (isoniazid and at least one additional first line drug), who had serologic evidence of HIV infection, 13 of whom were diagnosed with acquired immunodeficiency syndrome (AIDS). The MTB cultures from 10 out of 19 patients with MDR were resistant to three or more drugs. Fifteen patients died although 9 out of these 15 had received at least a four-drug regimen for a mean time of seven weeks (range 2 to 12). This increase in MDR was seen in ten homosexuals and nine intravenous drug users. This rapid appearance of MDR-MTB strains is worrisome. New strategies for empiric therapy of such patients while awaiting sensitivity data are needed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516405     DOI: 10.1378/chest.102.3.797

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

1.  Total synthesis of an antigenic heptasaccharide motif found in the cell-wall lipooligosaccharide of Mycobacterium gordonae strain 989.

Authors:  Chinmoy Mukherjee; Anup Kumar Misra
Journal:  Glycoconj J       Date:  2008-02-19       Impact factor: 2.916

2.  Concise synthesis of a heptasaccharide antigen found in the cell-wall lipopolysaccharide of Mycobacterium gordonae strain 990.

Authors:  Rajib Panchadhayee; Anup Kumar Misra
Journal:  Glycoconj J       Date:  2008-06-21       Impact factor: 2.916

3.  A comparison of the T cell delayed-type hypersensitivity epitopes of the 19-kD antigens from Mycobacterium tuberculosis and Myco. intracellulare using overlapping synthetic peptides.

Authors:  J C Mackall; G H Bai; D A Rouse; G R Armoa; F Chuidian; J Nair; S L Morris
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

4.  Study of Drug Resistant Pulmonary Tuberculosis.

Authors:  R B Deoskar; B Sengupta; K E Rajan; M S Barthwal; Jjj Falleiro; S K Sharma
Journal:  Med J Armed Forces India       Date:  2011-05-30

5.  Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.

Authors:  J Hafkin; C Modongo; C Newcomb; E Lowenthal; R R MacGregor; A P Steenhoff; H Friedman; G P Bisson
Journal:  Int J Tuberc Lung Dis       Date:  2013-01-14       Impact factor: 2.373

6.  Prospective study of drug-resistant tuberculosis in a Spanish urban population including patients at risk for HIV infection.

Authors:  V Ausina; N Riutort; B Viñado; J M Manterola; J Ruiz Manzano; C Rodrigo; L Matas; M Giménez; J Tor; J Roca
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

Review 7.  New developments in tuberculosis and HIV infection: an opportunity for prevention.

Authors:  J R Curtis; T M Hooton; C M Nolan
Journal:  J Gen Intern Med       Date:  1994-05       Impact factor: 5.128

8.  Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. AIDS in Europe Study Group.

Authors:  T V Perneger; P Sudre; J D Lundgren; B Hirschel
Journal:  BMJ       Date:  1995-12-02

9.  Purification of a novel coenzyme F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatis.

Authors:  E Purwantini; L Daniels
Journal:  J Bacteriol       Date:  1996-05       Impact factor: 3.490

Review 10.  Tuberculosis in the AIDS era.

Authors:  K A Sepkowitz; J Raffalli; L Riley; T E Kiehn; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.